12/2017: Four projects successfully completed in Q4


Laronidase, Ipilimumab, Natalizumab, Pembrolizumab.

 


These 4 cell line development projects were successfully finalized in Q4. Ready-to-use Research Cell Banks are available for out-licensing now!



Contact

UGA Biopharma GmbH
Neuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail:  info@ugabiopharma.com This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +49(0)3302 / 2024900